Clinical trial
Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate…
NCT00219271 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00219271 |
|---|---|
| Title | Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer |
| Official title | Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Collaborators | University of Athens |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | Zoledronic acid |
| Enrollment | 60 |
| Start date | Sep 1, 2003 |
| Primary completion | Sep 1, 2009 |
| Completion | Sep 1, 2009 |
| First posted | Sep 22, 2005 |
| Last update posted | May 31, 2017 |
| Countries | Greece |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: